RU2011118511A - Применение слитого конструкта тимп-гфи и способ ингибирования пролиферации раковых клеток для лечения рака - Google Patents
Применение слитого конструкта тимп-гфи и способ ингибирования пролиферации раковых клеток для лечения рака Download PDFInfo
- Publication number
- RU2011118511A RU2011118511A RU2011118511/10A RU2011118511A RU2011118511A RU 2011118511 A RU2011118511 A RU 2011118511A RU 2011118511/10 A RU2011118511/10 A RU 2011118511/10A RU 2011118511 A RU2011118511 A RU 2011118511A RU 2011118511 A RU2011118511 A RU 2011118511A
- Authority
- RU
- Russia
- Prior art keywords
- cancer
- timp
- use according
- gpi
- treatment
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract 16
- 201000011510 cancer Diseases 0.000 title claims abstract 16
- 230000004927 fusion Effects 0.000 title claims abstract 7
- 238000000034 method Methods 0.000 title claims 3
- 230000009702 cancer cell proliferation Effects 0.000 title claims 2
- 230000002401 inhibitory effect Effects 0.000 title claims 2
- 108010005246 Tissue Inhibitor of Metalloproteinases Proteins 0.000 claims abstract 10
- 102000005876 Tissue Inhibitor of Metalloproteinases Human genes 0.000 claims abstract 10
- 229930004094 glycosylphosphatidylinositol Natural products 0.000 claims abstract 8
- 206010009944 Colon cancer Diseases 0.000 claims abstract 6
- 239000012634 fragment Substances 0.000 claims abstract 6
- 208000008839 Kidney Neoplasms Diseases 0.000 claims abstract 4
- 206010038389 Renal cancer Diseases 0.000 claims abstract 4
- 208000029742 colonic neoplasm Diseases 0.000 claims abstract 4
- 201000010982 kidney cancer Diseases 0.000 claims abstract 4
- 206010006187 Breast cancer Diseases 0.000 claims abstract 3
- 208000026310 Breast neoplasm Diseases 0.000 claims abstract 3
- 239000003814 drug Substances 0.000 claims abstract 3
- 210000004881 tumor cell Anatomy 0.000 claims abstract 3
- 208000003174 Brain Neoplasms Diseases 0.000 claims abstract 2
- 108010084313 CD58 Antigens Proteins 0.000 claims abstract 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims abstract 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims abstract 2
- 208000009129 Ear Neoplasms Diseases 0.000 claims abstract 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims abstract 2
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims abstract 2
- 208000032612 Glial tumor Diseases 0.000 claims abstract 2
- 206010018338 Glioma Diseases 0.000 claims abstract 2
- 101000669513 Homo sapiens Metalloproteinase inhibitor 1 Proteins 0.000 claims abstract 2
- 208000005016 Intestinal Neoplasms Diseases 0.000 claims abstract 2
- 206010025323 Lymphomas Diseases 0.000 claims abstract 2
- 102000005741 Metalloproteases Human genes 0.000 claims abstract 2
- 108010006035 Metalloproteases Proteins 0.000 claims abstract 2
- 102100024289 Metalloproteinase inhibitor 4 Human genes 0.000 claims abstract 2
- 108050006579 Metalloproteinase inhibitor 4 Proteins 0.000 claims abstract 2
- 206010029260 Neuroblastoma Diseases 0.000 claims abstract 2
- 208000010505 Nose Neoplasms Diseases 0.000 claims abstract 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims abstract 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims abstract 2
- 206010060862 Prostate cancer Diseases 0.000 claims abstract 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims abstract 2
- 108010076504 Protein Sorting Signals Proteins 0.000 claims abstract 2
- 208000015634 Rectal Neoplasms Diseases 0.000 claims abstract 2
- 201000010208 Seminoma Diseases 0.000 claims abstract 2
- 208000000453 Skin Neoplasms Diseases 0.000 claims abstract 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims abstract 2
- 206010043276 Teratoma Diseases 0.000 claims abstract 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims abstract 2
- 108010031374 Tissue Inhibitor of Metalloproteinase-1 Proteins 0.000 claims abstract 2
- 102000005353 Tissue Inhibitor of Metalloproteinase-1 Human genes 0.000 claims abstract 2
- 108010031372 Tissue Inhibitor of Metalloproteinase-2 Proteins 0.000 claims abstract 2
- 102000005354 Tissue Inhibitor of Metalloproteinase-2 Human genes 0.000 claims abstract 2
- 108010031429 Tissue Inhibitor of Metalloproteinase-3 Proteins 0.000 claims abstract 2
- 102000005406 Tissue Inhibitor of Metalloproteinase-3 Human genes 0.000 claims abstract 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims abstract 2
- 208000002495 Uterine Neoplasms Diseases 0.000 claims abstract 2
- 201000005188 adrenal gland cancer Diseases 0.000 claims abstract 2
- 208000024447 adrenal gland neoplasm Diseases 0.000 claims abstract 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 2
- 239000000427 antigen Substances 0.000 claims abstract 2
- 102000036639 antigens Human genes 0.000 claims abstract 2
- 108091007433 antigens Proteins 0.000 claims abstract 2
- 210000000170 cell membrane Anatomy 0.000 claims abstract 2
- 201000010881 cervical cancer Diseases 0.000 claims abstract 2
- 201000004101 esophageal cancer Diseases 0.000 claims abstract 2
- 206010017758 gastric cancer Diseases 0.000 claims abstract 2
- 201000005787 hematologic cancer Diseases 0.000 claims abstract 2
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims abstract 2
- 201000002313 intestinal cancer Diseases 0.000 claims abstract 2
- 208000032839 leukemia Diseases 0.000 claims abstract 2
- 201000007270 liver cancer Diseases 0.000 claims abstract 2
- 208000014018 liver neoplasm Diseases 0.000 claims abstract 2
- 201000010453 lymph node cancer Diseases 0.000 claims abstract 2
- 210000004698 lymphocyte Anatomy 0.000 claims abstract 2
- 238000004519 manufacturing process Methods 0.000 claims abstract 2
- 239000011159 matrix material Substances 0.000 claims abstract 2
- 201000001441 melanoma Diseases 0.000 claims abstract 2
- 206010038038 rectal cancer Diseases 0.000 claims abstract 2
- 201000001275 rectum cancer Diseases 0.000 claims abstract 2
- 201000000849 skin cancer Diseases 0.000 claims abstract 2
- 201000011549 stomach cancer Diseases 0.000 claims abstract 2
- 201000002510 thyroid cancer Diseases 0.000 claims abstract 2
- 206010046766 uterine cancer Diseases 0.000 claims abstract 2
- 210000004027 cell Anatomy 0.000 claims 3
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 2
- 208000007660 Residual Neoplasm Diseases 0.000 claims 2
- 208000015347 renal cell adenocarcinoma Diseases 0.000 claims 2
- 238000001356 surgical procedure Methods 0.000 claims 2
- 206010003571 Astrocytoma Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010027476 Metastases Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 230000000259 anti-tumor effect Effects 0.000 claims 1
- 230000001640 apoptogenic effect Effects 0.000 claims 1
- 230000006907 apoptotic process Effects 0.000 claims 1
- 239000003599 detergent Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 239000000565 sealant Substances 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 abstract 1
- 230000002611 ovarian Effects 0.000 abstract 1
- 201000002528 pancreatic cancer Diseases 0.000 abstract 1
- 208000008443 pancreatic carcinoma Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/57—Protease inhibitors from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
- A61K47/544—Phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- C07K14/8146—Metalloprotease (E.C. 3.4.24) inhibitors, e.g. tissue inhibitor of metallo proteinase, TIMP
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Marine Sciences & Fisheries (AREA)
- Genetics & Genomics (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Abstract
1. Применение слитого конструкта, включающего аминокислотную последовательность тканевого ингибитора металлопротеиназ (ТИМП) или его биологически активного фрагмента, где биологически активный фрагмент ингибирует активные металлопротеиназы матрицы и кодируется любой из последовательностей SEQ ID NO 1 или 4, в которой указанный ТИМП или его биологически активный фрагмент связан с якорем гликозилфосфатидилинозита (ГФИ) для приготовления лекарственного средства для лечения рака. ! 2. Применение по п.1, в котором указанный ТИМП выбран из группы, состоящей из ТИМП-1, ТИМП-2, ТИМП-3, или ТИМП-4. ! 3. Применение по п.1, в котором указанный ТИМП представляет собой человеческий ТИМП-1. ! 4. Применение по п.1, в котором указанный слитый конструкт содержит одну или больше сигнальных последовательностей ГФИ, чтобы направить фиксацию ГФИ. ! 5. Применение по п.1, в котором указанный ГФИ-якорь получают из антигена, связанного с функцией лимфоцитов (LFA-3) или его части. ! 6. Применение по п.1 для лечения рака, в котором указанный конструкт ТИМП-ГФИ внедряют в клеточные мембраны опухолевых клеток. ! 7. Применение по п.1 для лечения рака, в котором указанный рак представляет собой: рак молочной железы, почечный рак, рак простаты, лейкозы, семиномы, меланомы, тератомы, лимфомы, нейробластомы, глиомы, ректальный рак, внутриматочный рак, почечный рак, рак надпочечников, рак щитовидной железы, рак крови, рак кожи, рак мозга, рак шейки матки, кишечный рак, рак печени, рак толстой кишки, рак желудка, рак кишки, желудочно-кишечный рак, рак лимфатических узлов, рак пищевода, колоректальный рак, рак поджелудочной железы, рак ухо, нос и горло (ENT), рак матки, овариальны
Claims (15)
1. Применение слитого конструкта, включающего аминокислотную последовательность тканевого ингибитора металлопротеиназ (ТИМП) или его биологически активного фрагмента, где биологически активный фрагмент ингибирует активные металлопротеиназы матрицы и кодируется любой из последовательностей SEQ ID NO 1 или 4, в которой указанный ТИМП или его биологически активный фрагмент связан с якорем гликозилфосфатидилинозита (ГФИ) для приготовления лекарственного средства для лечения рака.
2. Применение по п.1, в котором указанный ТИМП выбран из группы, состоящей из ТИМП-1, ТИМП-2, ТИМП-3, или ТИМП-4.
3. Применение по п.1, в котором указанный ТИМП представляет собой человеческий ТИМП-1.
4. Применение по п.1, в котором указанный слитый конструкт содержит одну или больше сигнальных последовательностей ГФИ, чтобы направить фиксацию ГФИ.
5. Применение по п.1, в котором указанный ГФИ-якорь получают из антигена, связанного с функцией лимфоцитов (LFA-3) или его части.
6. Применение по п.1 для лечения рака, в котором указанный конструкт ТИМП-ГФИ внедряют в клеточные мембраны опухолевых клеток.
7. Применение по п.1 для лечения рака, в котором указанный рак представляет собой: рак молочной железы, почечный рак, рак простаты, лейкозы, семиномы, меланомы, тератомы, лимфомы, нейробластомы, глиомы, ректальный рак, внутриматочный рак, почечный рак, рак надпочечников, рак щитовидной железы, рак крови, рак кожи, рак мозга, рак шейки матки, кишечный рак, рак печени, рак толстой кишки, рак желудка, рак кишки, желудочно-кишечный рак, рак лимфатических узлов, рак пищевода, колоректальный рак, рак поджелудочной железы, рак ухо, нос и горло (ENT), рак матки, овариальный рак и рак легкого и их метастазы.
8. Применение по п.1 для лечения рака, в котором указанный рак представляет собой остаточный рак после хирургического удаления.
9. Применение по п.1 для лечения рака, в котором слитый конструкт вводят местно в качестве противоопухолевого вспомогательного средства для лечения остаточного рака у больных раком молочной железы и у больных глиобластомой (астроцитома VI).
10. Применение по п.1, в котором слитый конструкт вводят в концентрации 0,5-5 мкг/мл, предпочтительно 1 мкг/мл.
11. Применение по п.1 для лечения рака, в котором указанный слитый конструкт вводят распылением в рану и/или инъекцией в области, которые не доступны для хирургии.
12. Способ ингибирования пролиферации раковых клеток in vitro, включающий стадию обработки раковых клеток эффективным количеством слитого конструкта ТИМП-ГФИ.
13. Способ по п.12, в котором указанная клетка представляет собой клетку почечно-клеточного рака (ПКР).
14. Применение ТИМП-ГФИ для придания опухолевым клеткам, устойчивым к FAS-апоптозу, чувствительности к FAS-индуцированному апоптозу.
15. Применение по п.1, в котором лекарственное средство применяют вместе с детергентом, герметиком или носителем.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05020462.7 | 2005-09-20 | ||
| EP05020462A EP1764372B1 (en) | 2005-09-20 | 2005-09-20 | Tissue inhibitor of metalloproteinases (TIMP) linked to glycosylphosphatidylinositol (GPI)-anchors for treatment of cancer |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2008108940/10A Division RU2428479C2 (ru) | 2005-09-20 | 2006-09-20 | Применение слитого конструкта тимп-гфи и способ лечения повреждений кожи для предотвращения или ингибирования образования рубца |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2011118511A true RU2011118511A (ru) | 2012-11-20 |
Family
ID=35456001
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2008108940/10A RU2428479C2 (ru) | 2005-09-20 | 2006-09-20 | Применение слитого конструкта тимп-гфи и способ лечения повреждений кожи для предотвращения или ингибирования образования рубца |
| RU2011118511/10A RU2011118511A (ru) | 2005-09-20 | 2011-05-10 | Применение слитого конструкта тимп-гфи и способ ингибирования пролиферации раковых клеток для лечения рака |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2008108940/10A RU2428479C2 (ru) | 2005-09-20 | 2006-09-20 | Применение слитого конструкта тимп-гфи и способ лечения повреждений кожи для предотвращения или ингибирования образования рубца |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US9255139B2 (ru) |
| EP (2) | EP1764372B1 (ru) |
| JP (2) | JP5645362B2 (ru) |
| CN (1) | CN101268102B (ru) |
| AT (2) | ATE439383T1 (ru) |
| AU (1) | AU2006299179B2 (ru) |
| BR (2) | BRPI0622293A2 (ru) |
| CA (2) | CA2860269C (ru) |
| DE (2) | DE602005015973D1 (ru) |
| DK (2) | DK1764372T3 (ru) |
| ES (2) | ES2331252T3 (ru) |
| HK (1) | HK1112923A1 (ru) |
| IL (2) | IL189924A (ru) |
| RU (2) | RU2428479C2 (ru) |
| SG (1) | SG173367A1 (ru) |
| WO (1) | WO2007039109A1 (ru) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2595778A1 (en) | 2005-01-28 | 2006-08-03 | Ramot At Tel Aviv University, Ltd. | Anti-muc1 .alpha..beta. antibodies |
| PT2185197T (pt) * | 2007-08-22 | 2019-01-21 | Noveome Biotherapeutics Inc | Novas composições de solução contendo fator celular e sua utilização para o tratamento de feridas |
| EP2143442A1 (en) * | 2008-07-11 | 2010-01-13 | Peter Jon Nelson | Treatment of solid tumors with tissue inhibitors of metalloproteinases(TIMPs) |
| CN106370857A (zh) | 2008-10-21 | 2017-02-01 | 阿斯图特医药公司 | 用于诊断和预后肾损伤和肾衰竭的方法和组合物 |
| EP2324847A1 (en) | 2009-11-24 | 2011-05-25 | Peter Jon Nelson | Acceleration of wound healing by a tissue inhibitor of metalloproteinases (TIMP) linked to glycosylphosphatidylinositol (GPI)-anchors |
| NZ605698A (en) | 2010-06-23 | 2015-03-27 | Astute Medical Inc | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| EP3575316A1 (en) * | 2014-08-27 | 2019-12-04 | Amgen, Inc | Variants of tissue inhibitor of metalloproteinase type three (timp-3), compositions and methods |
| JP6128700B2 (ja) * | 2015-05-21 | 2017-05-17 | 株式会社サンセイアールアンドディ | 遊技機 |
| CN105601733B (zh) * | 2016-02-01 | 2018-11-16 | 南通大学 | 抗CAV的多肽类似物和对应的cDNA及应用 |
| WO2018087757A1 (en) * | 2016-11-09 | 2018-05-17 | The National Institute for Biotechnology in the Negev Ltd. | Matrix metalloproteinase inhibitors and methods of use thereof |
| US20190352373A1 (en) * | 2017-01-25 | 2019-11-21 | Tessa Therapeutics Pte. Ltd. | TGF-ß DECOY RECEPTOR |
| CN110431422A (zh) | 2017-02-06 | 2019-11-08 | 机敏医药股份有限公司 | 用于肾损伤和肾衰竭的诊断和预后的方法和组合物 |
| US11058804B2 (en) * | 2017-06-13 | 2021-07-13 | Ethicon Llc | Surgical fastener device for the prevention of ECM degradation |
| CN109422816B (zh) * | 2017-08-25 | 2020-11-20 | 诺未科技（北京）有限公司 | 一种靶向次级淋巴组织的肝癌疫苗 |
| CN107961394B (zh) * | 2017-10-27 | 2020-10-13 | 南开大学 | 基于三元融合蛋白的抗hpv宫颈护创敷料设计 |
| KR102111025B1 (ko) * | 2018-06-05 | 2020-05-15 | 고려대학교 산학협력단 | 신경줄기세포 배양액을 유효성분으로 함유하는 항노화 또는 주름억제용 화장료 조성물 및 이의 제조 방법 |
| KR102081239B1 (ko) * | 2018-09-10 | 2020-02-25 | 고려대학교 산학협력단 | Timp-1 및 timp-2를 유효성분으로 함유하는 기형종 형성 및 성장 억제용 조성물 |
| CN109279627B (zh) * | 2018-11-09 | 2023-12-05 | 中盐枣阳盐化有限公司 | 一种盐硝固体分离工艺及化工装置 |
| JP2022535784A (ja) * | 2019-05-29 | 2022-08-10 | フブロ セラピューティクス エーエス | ペプチド |
| WO2021087839A1 (zh) * | 2019-11-07 | 2021-05-14 | 武汉华大吉诺因生物科技有限公司 | 肿瘤特异性多肽序列及其应用 |
| CN113832115A (zh) * | 2021-08-25 | 2021-12-24 | 居颂光 | 融合基因ril-7联合ccl19重组溶瘤牛痘病毒及其在制备抗肿瘤药物中的应用 |
| GB202114441D0 (en) | 2021-10-08 | 2021-11-24 | Reneuron Ltd | Proteins and extracellular vesicles |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1129666C (zh) * | 1994-12-13 | 2003-12-03 | 人体基因组科学有限公司 | 金属蛋白酶－4的人组织抑制剂 |
| US6544761B2 (en) * | 1994-12-13 | 2003-04-08 | Human Genome Sciences, Inc. | Human tissue inhibitor of metalloproteinase-4 |
| WO2001057068A1 (en) * | 2000-02-01 | 2001-08-09 | The Austin Research Institute | Mucin-1 derived antigens and their use in immunotherapy |
| US20020010162A1 (en) * | 2000-03-02 | 2002-01-24 | Raul Fleischmajer | Treatment of psoriasis with matrix metalloproteinase inhibitors |
| CN1338305A (zh) * | 2000-08-21 | 2002-03-06 | 杭州泰士生物科技有限公司 | 基质金属蛋白酶组织抑制剂预防和治疗血管损伤后再狭窄 |
| CN1398639A (zh) * | 2001-02-19 | 2003-02-26 | 王明生 | Timp－4基因作为制备临床治疗心血管和疤痕修复药中的应用 |
| SE0200667D0 (sv) * | 2002-03-05 | 2002-03-05 | A & Science Invest Ab | Novel use of cytokine inhibitors |
| CN1162185C (zh) * | 2002-11-01 | 2004-08-18 | 北京深文科技开发有限责任公司 | 基质金属蛋白酶组织抑制剂在制备预防和治疗关节炎病药的应用 |
-
2005
- 2005-09-20 AT AT05020462T patent/ATE439383T1/de active
- 2005-09-20 ES ES05020462T patent/ES2331252T3/es active Active
- 2005-09-20 EP EP05020462A patent/EP1764372B1/en not_active Not-in-force
- 2005-09-20 DK DK05020462T patent/DK1764372T3/da active
- 2005-09-20 DE DE602005015973T patent/DE602005015973D1/de active Active
-
2006
- 2006-09-20 EP EP06805780A patent/EP1937725B1/en not_active Not-in-force
- 2006-09-20 DE DE602006012864T patent/DE602006012864D1/de active Active
- 2006-09-20 JP JP2008531605A patent/JP5645362B2/ja not_active Expired - Fee Related
- 2006-09-20 RU RU2008108940/10A patent/RU2428479C2/ru not_active IP Right Cessation
- 2006-09-20 CA CA2860269A patent/CA2860269C/en not_active Expired - Fee Related
- 2006-09-20 US US11/992,213 patent/US9255139B2/en not_active Expired - Fee Related
- 2006-09-20 CA CA2622042A patent/CA2622042C/en not_active Expired - Fee Related
- 2006-09-20 BR BRPI0622293-5A patent/BRPI0622293A2/pt not_active IP Right Cessation
- 2006-09-20 DK DK06805780.1T patent/DK1937725T3/da active
- 2006-09-20 AU AU2006299179A patent/AU2006299179B2/en not_active Ceased
- 2006-09-20 ES ES06805780T patent/ES2342425T3/es active Active
- 2006-09-20 SG SG2011050408A patent/SG173367A1/en unknown
- 2006-09-20 AT AT06805780T patent/ATE460432T1/de active
- 2006-09-20 BR BRPI0616093-0A patent/BRPI0616093A2/pt active Search and Examination
- 2006-09-20 WO PCT/EP2006/009145 patent/WO2007039109A1/en active Application Filing
- 2006-09-20 CN CN2006800343518A patent/CN101268102B/zh not_active Expired - Fee Related
-
2008
- 2008-03-04 IL IL189924A patent/IL189924A/en not_active IP Right Cessation
- 2008-07-17 HK HK08107922.0A patent/HK1112923A1/xx not_active IP Right Cessation
-
2011
- 2011-05-10 RU RU2011118511/10A patent/RU2011118511A/ru not_active Application Discontinuation
- 2011-05-12 IL IL212867A patent/IL212867A/en not_active IP Right Cessation
-
2013
- 2013-06-06 JP JP2013119610A patent/JP2013240326A/ja active Pending
-
2016
- 2016-01-19 US US15/000,928 patent/US20160271234A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2011118511A (ru) | Применение слитого конструкта тимп-гфи и способ ингибирования пролиферации раковых клеток для лечения рака | |
| Erler et al. | Hypoxia-induced lysyl oxidase is a critical mediator of bone marrow cell recruitment to form the premetastatic niche | |
| CY1117759T1 (el) | Ενα καινουργιο φαρμακευτικο παρασκευασμα για την προ-εκλαμψια | |
| EP3227322B1 (en) | Cd44v6-derived cyclic peptides for treating cancers and angiogenesis related diseases | |
| RU2007145489A (ru) | Фармацевтические композиции и способы лечения рака и его метастазов | |
| Kim et al. | Membrane proteins involved in epithelial-mesenchymal transition and tumor invasion: studies on TMPRSS4 and TM4SF5 | |
| Lee et al. | Proctocolectomy for ulcerative colitis | |
| CN102850443B (zh) | 整合素阻断剂多肽及其应用 | |
| Chikina et al. | The cellular mechanisms and regulation of metastasis formation | |
| CN114159446A (zh) | 组织蛋白酶c抑制剂在治疗肿瘤转移中的应用 | |
| RU2011108486A (ru) | ПРИМЕНЕНИЕ ПРОИЗВОДНЫХ ПЕПТИДА Wnt5-a ДЛЯ ЛЕЧЕНИЯ МЕЛАНОМЫ И РАКА ЖЕЛУДКА | |
| CA3148827A1 (en) | Compositions and methods of using c/ebp alpha sarna | |
| Idiiatullina et al. | EnDuo, a novel derivative of Endostar, inhibits the migration of colon cancer cells, suppresses matrix metalloproteinase-2/9 expression and impedes AKT/ERK activation | |
| DE60041974D1 (de) | 5-methylindirubin zur verwendung in der behandlung von menschlichen festen tumoren | |
| Orellana et al. | Connexins in melanoma: Potential role of Cx46 in its aggressiveness | |
| CU22979A1 (es) | Combinación inmunoterapéutica para el tratamiento de tumores que sobre-expresan receptores con actividad quinasa en residuos de tirosina | |
| ATE369147T1 (de) | Verwendung von stimulierten mononuklearen zellen des peripheren blutes zur behandlung von krebserkrankungen | |
| JPWO2020160180A5 (ru) | ||
| CN100484575C (zh) | 一类封闭myc细胞增殖途径的染色质肽药物分子 | |
| Fujita et al. | Involvement of integrin-activating peptides derived from tenascin-C in colon cancer progression | |
| Wang et al. | Alteronol inhibits the invasion and metastasis of B16F10 and B16F1 melanoma cells in vitro and in vivo | |
| Ren et al. | Knockdown of NLE1 inhibits development of malignant melanoma in vitro and in vivo NLE1 promotes development of malignant melanoma | |
| RU2012100903A (ru) | Терапевтические пептиды, полипептиды и последовательности нуклеиновых кислот | |
| RU2465843C1 (ru) | Способ адъювантной терапии местно-распространенного рака желудка | |
| CN106279399A (zh) | 趋化素修饰胜肽 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA94 | Acknowledgement of application withdrawn (non-payment of fees) |
Effective date: 20160217 |